A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Modified immune cells are provided, the modified immune cells expressing a heterologous polynucleotide comprising a nucleotide sequence encoding a function (e.g., at least one of persistence, proliferation, or cytotoxicity) booster, e.g., an apoptosis inhibitor. In one aspect, the modified T cells further comprise a chimeric antigen receptor. Methods, kits, and components for making and using the modified immune cells are also provided.
This disclosure provides compounds, pharmaceutical compositions, imaging compositions and methods useful for the diagnosis and/or treatment of neurodegenerative diseases. In particular, this disclosure provides compounds, including radiolabeled compounds, compositions, and methods useful for the diagnosis and/or treatment of neurodegenerative diseases associated with a-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, multiple systems atrophy or prodromal REM sleep behavior disorder.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
C07C 13/47 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing ten carbon atoms
C07D 251/14 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
A method of preventing or treating COVID infection in a subject includes selecting two or more COVED CTL epitopes from a Coronavirus proteome that have a network score that meets a threshold value. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected Coronavirus CTL epitopes.
Antibody derivatives that have diminished effector function in the initial state owing to the presence of one or more disabling moieties that substantially prevent engagement of the antibody regions responsible for interaction with humoral and cellular immune system effector molecules, and methods of use thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
6.
METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS
Disclosed are methods of identifying a cross-modal feature from two or more spatially resolved data sets, the method including: (a) registering the two or more spatially resolved data sets to produce an aligned feature image including the spatially aligned two or more spatially resolved data sets; and (b) extracting the cross-modal feature from the aligned feature image.
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
An apparatus for directing optical energy onto a sample, including: a difference frequency generation (DFG) laser apparatus; a handpiece optically coupled to at least a portion of the DFG laser apparatus by an optical fiber arrangement; and a controller in operative communication with the DFG laser apparatus and the handpiece, wherein the DFG laser apparatus is configured to generate both ablative and nonablative optical energy, and wherein the handpiece includes at least one of an optical or a micromechanical element configured to generate a first pulse and a second pulse of optical energy, wherein a first amount of at least one of ablative optical energy or nonablative optical energy in the first pulse is different from a second amount of at least one of ablative optical energy or nonablative optical energy in the second pulse, and wherein the controller is configured to direct the first pulse and the second pulse onto a particular location on the sample using the handpiece.
The present disclosure relates to treating mitochondrial diseases, cancer and other conditions as a result of reduced oxidative phosphorylation (OXPHOS) activity by overexpressing the METTL17 gene, encoding methyltransferase-like 17. Currently, overexpression of METTL17 to increase its copy number and/or intra-mitochondrial activity has not been indicated as a possible therapeutic for treating mitochondrial disease or other diseases such as cancer or aging related to a decline in OXPHOS activity. A variety of gene therapy approaches are presented for overexpression of METTL17 including, but not limited to, AAV, adenovirus and lentiviral vector expression.
Described are antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or myeloid-derived suppressor cells (MDSCs), to expand T effector cell populations or function, and to reduce the proliferation of, or directly kill, tumor cells, such as tumor cells that express TNFR2 antigen. The polypeptides, such as antibodies and antigen-binding fragments thereof, are TNFR2 antagonists, such as dominant TNFR2 antagonists. The polypeptides can be used to suppress the T-reg- or MDSC-mediated deactivation of tumor reactive T lymphocytes, expand populations of tumor-reactive cytotoxic T cells, and/or to directly kill TNFR2+ tumor cells. The antagonistic TNFR2 polypeptides described herein can be used to treat a wide variety of cancers and infectious diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are natural killer (NK) cells with increased, modified or deleted extracellular matrix (ECM) receptors, and methods of making and using the same for cancer immunotherapy, and treatment of chronic infections, inflammation, autoimmune diseases, or transplant rejection.
Systems and methods are provided for patient monitoring and/or treatment. The system may include one or more sensors configured to measure electroencephalogram (EEG) and electrodermal signals of a patient subject to at least one anesthetic agent and at least one analgesic agent during an operative medical procedure. The system can also include a processor, operably coupled to the one or more sensors. The processor is configured to receive the EEG and electrodermal signals and, using the EEG or electrodermal signals, generate a report indicating the nociceptive state of the patient in real-time during the operative medical procedure while the patient is subject to the at least one anesthetic and a pain management plan based on desired post-operative outcomes..
A61B 5/316 - Modalities, i.e. specific diagnostic methods
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Modified immune cells are provided, the modified immune cells expressing a heterologous polynucleotide comprising a nucleotide sequence encoding a function (e.g., at least one of persistence, proliferation, or cytotoxicity) booster, e.g., an apoptosis inhibitor. In one aspect, the modified T cells further comprise a chimeric antigen receptor. Methods, kits, and components for making and using the modified immune cells are also provided.
An injectable nanoparticular formulation and method of use thereof for treating non-compressible hemorrhage or internal bleeding has been developed. The formulation includes two interactive components, one a targeting nanoparticle with a polypeptide sequence that binds to a cell present at a site of injury, and the other a crosslinking nanoparticle with a bioorthogonal click-crosslinking group.
Improved compositions and methods for generating chondrocytes and cartilage tissues from human pluripotent stem cells are provided. Methods include use of one or more of FGF agonist,cAMP agonist, and TGFβ agonist to induce chondrogenesis in monolayer culture. Articular cartilage tissues generated using the methods have zonal organization similar to native cartilage tissue including surface chondrocytes and intermediate zone chondrocytes, with increased extracellular matrix components consistent with native cartilage tissue. These biochemical and mechanical properties make the cartilage tissue particularly suited for tissue implants in vivo.
As described below, the present invention features compositions, panels of biomarkers, and methods for characterizing chronic lymphocytic leukemia (CLL) for prognosis and selection of a subject for a treatment and/or inclusion in a clinical trial.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
18.
SYSTEMS AND METHODS FOR IN VIVO CHARACTERIZATION OF TUBULAR SOFT TISSUES
Systems and methods described herein can facilitate in vivo characterization of soft tissue, such as within a colon or other areas of a gut, by providing one or more of a geometric variable or a biomechanical response variable. For example, a tissue characterization system can include a control system, a pressure transducer, and a catheter. The system can measure pressure and diameter data of a soft tissue region or interest. The pressure and diameter data can be analyzed to provide a gut stiffness index that corresponds to various characterizations of the region of interest, such as an extent of gut fibrosis, a severity of mucosa damage, or an infiltration of immune cells
The disclosure provides compositions comprising an inhibitory nucleic acid targeting IncExACTI, and methods of use thereof to improve cardiac function in a subject in need thereof. Specifically, the disclosure provides a cardiac long noncoding RNA (IncRNA), referred as IncExACT 1 (SEQ ID NO: 1), and inhibitory nucleic acids targeting IncExACT 1 for reducing expression of IncExACT 1 and/or Dachsous cadherin-related 2 (DCHS2) in a cell, e.g., a cell in a subject for improving cardiac function in a subject, wherein the subject has pathological cardiac hypertrophy and/or heart failure.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
20.
Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions
The present application provides methods of functionalizing an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal or by culturing an organ or tissue in a bioreactor containing such nutrient. The present application also provides methods of selectively functionalizing extracellular matrix (ECM) of an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal. In some aspects, the present application provides a decellularized scaffold of a mammalian organ or tissue comprising an extracellular matrix, wherein the extracellular matrix of the decellularized scaffold is functionalized with a chemical group that is reactive in a bioorthogonal chemical reaction, such as an azide chemical group. The present application also provides biological prosthetic mesh and mammalian organs and tissues for transplantation prepared according to the methods of the application.
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
The United States of America, as represented by the Secretary, Department of Health and Human Servic (USA)
Yale University (USA)
The General Hospital Corporation (USA)
Inventor
Natarajan, Pradeep
Genovese, Giulio
Zekavat, Seyedeh Maryam
Machiela, Mitchell J.
Lin, Shu-Hong
Abstract
The invention features methods that are useful for treatment of a patient at increased risk for infection and for selecting a patient for treatment for an infection. In various embodiments, the infection is coronavirus disease 2019 (COVID-19), sepsis, or other respiratory infections.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
22.
SYSTEMS, METHODS, AND APPARATUS FOR DIFFERENTIAL PHASE CONTRAST MICROSCOPY BY TRANSOBJECTIVE DIFFERENTIAL EPI-DETECTION OF FORWARD SCATTERED LIGHT
Systems, methods, and apparatus for differential phase contrast microscopy by transobjective differential epi-detection of forward scattered light are provided. In some embodiments, a microscope objective comprises: a housing with mounting threads at a second end; optical components defining an optical axis, comprising: an objective lens mounted at a first end, configured to collect light from a sample placed in a field of view, the plurality of optical components create a pupil plane at a first distance along the optical axis at which rays having the same angle of incidence on the objective lens converge at the same radial distance from the optical axis; a photodetector within the housing offset from the optical axis at a second distance along the optical axis; and another photodetector within the housing at second distance along the optical axis and offset from the optical axis in the opposite direction from the first photodetector.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
The disclosure is directed, in part, to novel drug-responsive T cell factors providing temporal and/or spatial control over T cell (e.g., CAR T cell) activation and/or proliferation, T cells comprising the T cell factors, nucleic acid encoding the T cell factors, and methods for using and producing the same.
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
LIG1POLD1 XRCC1 LIG1 LIG1 LIG1 loss was also associated with higher chromosomal instability index (CIN) and poor prognosis in other cancer types, demonstrating that deletion of lagging- strand synthesis components has broad clinical significance.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
25.
INTERMEDIATE METABOLISM PRODUCTS TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS IN BACTERIAL INFECTIONS
Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and treatment with one or more proton motive force (PMF) stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known.
A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
An apparatus for obtaining image data and functional data from a biological sample, the apparatus including: an interferometer configured to acquire interferometric information at a plurality of time points along an imaging plane for which at least one axis of the plane is at least partially along a depth or axial dimension that is based on radiations provided from a reference interfered with by the biological sample; and a processor configured to receive the interferometric information from the interferometer and configured to: process the interferometric information to generate an image of the biological sample along the imaging plane; determine frequency information based on the plurality of time points of the interferometric information, the frequency information reflecting temporal modulations induced by dynamic functions of the biological sample; generate a spatial map of the frequency information, and the spatial map of the frequency information indicating the dynamic functions of the biological sample.
Cosmetic method and apparatus are provided that can provide cooling and/or freezing of skin tissue proximal to the skin surface to generate an appearance of lightening or reduced pigmentation in the skin. The skin can be cooled to a temperature of less than about -5° C. for a duration of about one minute or less, using a cooled surface that is at least 3 cm in width. A cooling arrangement can be provided to provide controlled heat removal from the skin tissue being treated. A sensor can optionally be provided to detect freezing of tissue proximal to the cooled surface.
A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body
A61F 7/02 - Compresses or poultices for effecting heating or cooling
A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
Provided herein are compounds that are able to bind metal ions (e.g., free metal ions or metal ions bound to low affinity ligands) in a sample or subject. Also provided herein are methods of using the compounds for chelating metal ions and for the treatment of diseases associated with abnormal levels of metal ions. Methods of preparing the compounds and pharmaceutical compositions are also provided.
The present invention provides for single-molecule profiling of combinatorial protein modifications and single-molecule profiling of combinatorial protein modifications combined with single-molecule sequencing of protein/nucleic acids complexes. High-throughput single-molecule imaging was applied to decode combinatorial modifications on millions of individual nucleosomes from pluripotent stem cells and lineage-committed cells. Applicants identified bivalent nucleosomes with concomitant repressive and activating marks, as well as other combinatorial modification states whose prevalence varies with developmental potency. Applying genetic and chemical perturbations of chromatin enzymes show a preferential affect on nucleosomes harboring specific modification states. The present invention also combines this proteomic platform with single-molecule DNA sequencing technology to simultaneously determine the modification states and genomic positions of individual nucleosomes. This novel single-molecule technology can be used to address fundamental questions in chromatin biology and epigenetic regulation leading to novel therapeutics and diagnostics.
Hydrogel beads having tunable rates of loading and unloading of cryoprotective agents are provided herein. Such hydrogel beads can be dispersed throughout a cell suspension to enable loading and unloading of cryoprotective agents from cells in a gradual and distributed manner that protects the cells from osmotic damage. Lymphocyte viability after cryopreservation is significantly greater when cryoprotective agents are loaded and unloaded using hydrogel beads compared to conventional media exchange methods.
Industry-Academic Cooperation Foundation, Yonsie Univsersity (Republic of Korea)
The General Hospital Corporation (USA)
Inventor
Cheon, Jinwoo
Lee, Jae-Hyun
Cheong, Jiyong
Yu, Ho Jeong
Lee, Hakho
Abstract
A point-of-care device for detecting nucleic acid is disclosed. The point-of-care device for detecting nucleic acid according to an exemplary embodiment of the present invention includes a rotating body in which a plurality of test tubes containing a sample mixed with heat-generating particles that generate heat when irradiated with light beams are radially coupled around a rotation shaft; a first actuator for rotating the rotating body such that the test tube rotates about the rotation shaft; and an irradiation module for irradiating the light beams to an irradiated area which is set on a rotation path of the test tube, wherein the rotation path includes a non-irradiated area to which the light beams are not irradiated, and wherein the test tube proceeds through the irradiated area and the non-irradiated area on the rotation path according to the rotation of the rotating body.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
B01L 7/00 - Heating or cooling apparatus; Heat insulating devices
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
33.
TAU MODULATORS AND METHODS AND COMPOSITIONS FOR DELIVERY THEREOF
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
Systems and methods are provided for evaluating a stability of a joint within the foot and ankle complex of a subject. The subject is instructed to assume a position in which the joint is bearing weight, and a three-dimensional medical image of the joint comprising a sequence of two-dimensional image slices is captured at a scanner. The sequence of two-dimensional image slices is provided to a predictive model, comprising an artificial neural network having at least one convolutional layer. A clinical parameter representing the stability of the joint at the predictive model is determined from at least the sequence of two-dimensional image slices.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
A cellular coding construct uniquely codes a cellular entity and includes a laser particle and a structurally coded oligonucleotide. The structurally coded oligonucleotide and the laser particle have a physical association with each other and are configured for physical association with the cellular entity and also configured for distinctive identification of the cellular entity.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
36.
IMPROVED METHODS FOR NEOPLASIA DETECTION FROM CELL FREE DNA
The invention features compositions and methods that are useful for determining the fraction of tumor-derived DNA (tumor fraction; TF) in cell free DNA (cfDNA). The methods involve calculating the fraction of tumor-derived DNA in the cfDNA using a combination of copy number alteration data and fragment length distribution data.
37.
PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF
Described herein are pancreatic ductal adenocarcinoma (PDAC) signatures and methods of detecting the same in a sample from a subject. Also described herein, are methods of methods of diagnosing, prognosing, and/or treating PDAC in a subject that can include detecting one or more of the PDAC signatures.
38.
NEURAL PROGENITOR CELL COMPOSITIONS AND METHODS OF USING THE SAME
The claimed invention is directed to compositions including adipose tissue-derived, for example, subcutaneous adipose tissue-derived or visceral adipose tissue-derived neuronal progenitor cells, and methods for the production and uses thereof.
The present disclosure relates to the use of a contact-type patch in a staining process. An exemplary method for quenching a fluorophore present in a biological sample includes contacting a surface of a quenching patch including a polymer-containing substrate and a quenching agent disposed within the substrate, with the biological sample.
A compact, portable linear scanning x-ray system includes a physically uncoupled x-ray source and x-ray detector that are each translatable along different respective scanning trajectories. The scanning trajectories may be linear scanning trajectories, which may be parallel linear scanning trajectories. The x-ray source and x-ray detector can be independently moveable. A controller aligns the x-ray source with the x-ray detector and synchronously moves the x-ray source and x-ray detector to obtain an image of an object. Artificial intelligence algorithms can be used to provide for automatic alignment and/or movement of the x-ray source and x-ray detector, which may be based on positioning sensors located on the x-ray source, the x-ray detector, or both.
Aspects of the present disclosure provide devices and methods for rapid, quantitative, on-site detection of controlled substances. Devices include a sample processing module and a sensor cartridge, and optionally a detection cradle.
Described herein are compositions and methods for treating cancer in a subject. Using the compositions and methods of the disclosure, a subject may be administered (i) an inhibitor and/or an overrider and (ii) a chemotherapeutic.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
43.
SYSTEMS AND METHODS FOR MONITORING AN ANALYTE OR PARAMETER FOR A PATIENT
A sensor system includes a probe, and a photon source configured to direct photons at the probe. The probe can emit light in response to receiving photons. The sensor system can include a photodetector configured to detect the light emitted from the probe, and a configured to cause the photon source to emit photons according to a first time-varying intensity profile having a first frequency. The controller can be configured to receive optical data from the photodetector based on the interaction between the light emitted from the probe and the photodetector. The optical data can include a second time-varying intensity profile having a second frequency. The second frequency can be substantially the same as the first frequency. The controller can be configured to determine a difference in phase between the first time-varying intensity profile and the second time-varying intensity profile, and generate a report based on the difference in phase.
Systems and devices for compressing a 5th metatarsal fracture of the foot are provided. A bone fixation device is provided that includes an opening for receiving a bone screw. The device also includes at least one hook sized and configured to be placed at the base of the 5th metatarsal bone of the foot. Drill guides and bone tap guides are also provided that include at least one hook sized and configured to placed at the base of the 5th metatarsal bone of the foot.
Systems and methods are provided for weight bearing images. A pressure sensor has a surface for receiving the feet of a patient while the patient is standing and generating pressure distribution map having a first region associated with a first foot of the patient and a second region associated with a second foot of the patient. An imager captures an image of a region of interest associated with the patient while the patient is standing on the sensor interface. A predictive model receives a representation of the first region and a representation of the second region and determines a value representing a stance of the patient. An output interface provides the value representing the stance of the patient to one of a display, the imager, and an image post-processing model.
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventor
Henary, Maged
Choi, Hak Soo
Kashiwagi, Satoshi
Abstract
The present invention is directed to squaraine fluorophores, methods of making squaraine fluorophores, and methods of using squaraine fluorophores. In some embodiments, squaraine fluorophores can be used as imaging agents, for example for imaging cancer. In some embodiments, the squaraine fluorophores can be used to guide surgical tumor resection.
Described herein are methods and compositions for treating cancer, fibrosis, and inflammation, and reducing risk of developing cancer, fibrosis, and inflammation, using small molecule inhibitors of IL-33, i.e., pitavastatin calcium, tropisetron, ammonium glycyrrhizinate, ticagrelor, and cetrimonium bromide.
A guiding apparatus, system, method, and forceps device for facilitating placement of sutures in a surgical procedure. The apparatus including a shaft portion having a non-circular aperture extending laterally therethrough and a blade portion having a shank extending at an angle from the shaft portion and a blade having a blade aperture extending from the shank. The system includes a plurality of the apparatuses held substantially parallel by an elongated rod through the apertures of the shafts. The blade apertures guide the at least one suture to a desired location to pierce through a target body tissue.
A61B 17/04 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for suturing wounds; Holders or packages for needles or suture materials
Systems and methods are provided for determining a clinical parameter via evaluation of sequential medical images. A sequence of at least three medical images for a patient are captured at a scanner. A set of at least two difference images are generated from the sequence of at least three medical images. Each difference image represents a difference in content between two adjacent images in the sequence of at least three medical images. The set of at least two difference images are provided to a predictive model. The predictive model includes an artificial neural network having at least one convolutional layer. A clinical parameter for the patient is determined at the predictive model from at least the set of at least two difference images.
G06T 5/50 - Image enhancement or restoration by the use of more than one image, e.g. averaging, subtraction
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
50.
SYSTEM FOR AND METHOD OF DEEP LEARNING DIAGNOSIS OF PLAQUE EROSION THROUGH OPTICAL COHERENCE TOMOGRAPHY
Korea Advanced Institute of Science and Technology (Republic of Korea)
Inventor
Jang, Ik-Kyung
Ye, Jong Chul
Park, Sangjoon
Abstract
A method for identifying plaque erosion in a vessel. The method includes: obtaining, using a processor, a sequence of images of the vessel; extracting, using the processor, one or more image features from the sequence of images using a convolutional neural network model; contextually classifying, using the processor, the one or more extracted image features using a cascaded self-attention trained model; and generating, using the processor, one or more diagnostic labels associated with the sequence of images based on contextually classifying the one or more extracted image features, where the one or more diagnostic labels may include an indication of a presence of plaque erosion or an absence of plaque erosion.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
The invention related to therapeutic polymeric materials and medical implants containing additives and/or analgesic agents. The invention also relates to methods of making therapeutic polymeric materials and medical implants containing additives and/or analgesic agents. Methods of spatially controlling additive concentrations and release as well as polymeric material morphology are also provided.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
52.
CHIMERIC ANTIGEN RECEPTORS BASED ON ALTERNATIVE SIGNAL 1 DOMAINS
Described herein are methods for producing and utilizing an alternative signal 1 domain to construct an optimally signaling CAR. Alternative signal 1 domains of the present technology are based on alternatives to CD3ζ, including mutated ITAMs from CD3ζ (which contains 3 IT AM motifs), truncations of CD3ζ, and alternative splice variants known as CD3s, CD3 theta, and artificial constructs engineered to express fusions between CD3s or CD30 and CD3ζ. CAR polypeptides comprising alternative signal 1 domains are utilized to engineer CAR T cells. Further, this technology related to methods of treating cancer by administering to a subject in need thereof CAR T cells comprising alternative signal 1 domains.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
53.
INTEGRATED MULTIPLEXED PHOTOMETRIC MODULE AND METHOD
Reusable network of spatially-multiplexed microfluidic channels each including an inlet, an outlet, and a cuvette in-between. Individual channels may operationally share a main or common output channel defining the network output and optionally leading to a disposable storage volume. Alternatively, multiple channels are structured to individually lead to the storage volume. An individual cuvette is dimensioned to substantially prevent the formation of air-bubbles during the fluid sample flow through the cuvette and, therefore, to be fully filled and fully emptied. The overall channel network is configured to spatially lock the fluidic sample by pressing such sample with a second fluid against a closed to substantially immobilize it to prevent drifting due to the change in ambient conditions during the measurement. Thereafter, the fluidic sample is flushed through the now-opened valve with continually-applied pressure of the second fluid. System and method for photometric measurements of multiple fluid samples employing such network of channels.
The invention is directed to a composition comprising cromolyn sodium and ibuprofen, wherein the cromolyn sodium is micronized and the cromolyn sodium and ibuprofen are present in a weight ratio of 1:1-2. In one embodiment, the ibuprofen is passed through a sieve, such as a 300 μm sieve and to methods of making the same.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61M 16/14 - Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
Described herein are methods comprising using measurements of perioperative plasma concentrations of Tau-PT217 and/or Tau-PT181 to predict which subjects are likely to develop postoperative delirium, and to thereby identify which patients are most likely to benefit from interventions to reduce risk or mitigate the severity or consequences of postoperative delirium.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
57.
SYSTEMS AND METHODS FOR ADMINISTERING A SMELL TEST FOR SARS CORONAVIRUSES AND COVID-19
Systems and methods ate provided that may facilitate the self-administration of an odor-based, or smell test. The test may include like patient performing an odor intensity test, odor identity test, and/or odor discrimination test using an odor proctor or testing kit. The testing kit can include the odor proctor and a test guide. The test guide may be used with the odor proctor to perform various smell test(s). The test guide may be realized in software that is readily available via a personal computing device.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
58.
METHOD AND APPARATUS FOR RECORDING MICROSCOPIC IMAGES FROMWITHIN A LIVING ORGANISM USING AN IMPLANTABLE DEVICE
Exemplary apparatus and method can be provided. For example, using at least one light source first arrangement, it is possible to provide pulses of light to at least one portion of a biological structure. At least one detector second arrangement can be used to detect images from the portion(s) based on the pulses, and provide data based on the detection. With at least one configuration, it is possible prevent and/or reduce a movement of the apparatus within at least one anatomical body (i) is a particular surface of the apparatus, (ii) covers at least one portion of the surface, and/or (iii) extends from the surface. In addition or alternatively, with at least one computer third arrangement, it is possible to receive the data, and control a timing of at least one of activation or deactivation of at least one portion of the first arrangement based on the data.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
Systems and methods for a coupling a percutaneous device. The system can include a first coupling that can be configured to connect to a first catheter extending through a percutaneous opening in a patient, a second coupling that can be configured to connect to a second catheter to fluidly connect to the first catheter, and a failure-release that can be configured to automatically disconnect the fluid connection between the first catheter and the second catheter upon the system receiving a force at or above a predetermined threshold to protect the percutaneous opening in the patient from the force.
An imaging tool, including: a drive shaft including a proximal end and a distal end; an optical waveguide including a proximal end and a distal end, the proximal end of the optical waveguide being disposed within the proximal end of the drive shaft, and the distal end of the optical waveguide extending beyond the distal end of the drive shaft; and an optical probe head coupled to the distal end of the optical waveguide.
A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for ears, i.e. otoscopes
A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
In accordance with some non-limiting examples of the disclosed subject matter, an ingestible system configured to acquire physiological information from an interior of a subject is provided, comprising a substrate and at least one physiological sensor. The at least one physiological sensor can be coupled to the substrate and configured to capture physiological data from at least one of an internal area or an orientation in a digestive tract of the subject. The system can include a controller coupled to the substrate and configured to receive the physiological data and prepare the physiological data for one of transmission from the subject or analysis of the physiological data. The substrate, including the at least one physiological sensor and the controller coupled thereto can be configured to self-orient within the digestive tract of the subject, during ingestion of the system by the subject. The substrate can additionally orient the at least one physiological sensor in the at least one of the internal area or the orientation in the digestive tract of the subject.
A61B 5/285 - Endotracheal, oesophageal or gastric probes
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
A61B 5/0537 - Measuring body composition by impedance, e.g. tissue hydration or fat content
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
Described herein are systems, methods, and compositions for the precise editing of DNA sequence(s) at specific loci to alter expression of target gene products at the pre-transcriptional or post-transcriptional level in a durable fashion, termed Stable and Heritable Alteration by Precision Editing (SHAPE). The SHAPE platform utilizes genetic modifiers (e.g., nucleases, (CRISPR guided) transposases, recombinases, base editors, and prime editors) to install specific sequence motifs at target sequences through precision genome engineering.
Systems/techniques that facilitate automated training of machine learning classification for patient missed care opportunities or late arrivals are provided. In various embodiments, a system can access a set of annotated data candidates defined by two or more feature categories. In various aspects, the system can train a machine learning classifier on the set of annotated data candidates, thereby causing internal parameters of the machine learning classifier to become iteratively updated. In various instances, the system rank the two or more feature categories in order of classification importance, based on the iteratively updated internal parameters of the machine learning classifier. In various cases, the system can perform one or more electronic actions based on the two or more feature categories being ranked in order of classification importance.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventor
Choi, Hak Soo
Kashiwagi, Satoshi
Henary, Maged, M.
Abstract
The present application provides pH-sensitive fluorophores, pharmaceutical compositions comprising pH-sensitive fluorophores, and methods for imaging of cancerous tumors comprising administering to the subject an effective amount of a compound or a pharmaceutical composition, waiting a time sufficient to allow the compound to accumulate in the cancerous tumor to be imaged, and imaging the cancerous tumor with a fluorescence imaging technique. Further provided methods of treating cancer, comprising imaging a cancerous tumor in a subject; and surgically removing the cancerous tumor from the subject.
Systems/techniques that facilitate automated training of machine learning classification for patient missed care opportunities or late arrivals are provided. In various embodiments, a system can access a set of annotated data candidates defined by two or more feature categories. In various aspects, the system can train a machine learning classifier on the set of annotated data candidates, thereby causing internal parameters of the machine learning classifier to become iteratively updated. In various instances, the system rank the two or more feature categories in order of classification importance, based on the iteratively updated internal parameters of the machine learning classifier. In various cases, the system can perform one or more electronic actions based on the two or more feature categories being ranked in order of classification importance.
Described herein are methods of determining segregation dynamics of mitochondrial DNA herein. Also described herein are methods of diagnosing, prognosing, and/or monitoring a mitochondrial disease.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
The present disclosure relates to compositions and methods for nucleic acid sequencing, and specifically, at least in certain aspects, provides methods and compositions for enhancing the efficacy, throughput and/or yield of known long-range sequencing platforms, by providing chimeric arrays of input sequences. Such arrays of component nucleic acid sequence elements can be prepared via methods that minimize introduction of bias. The application of the current methods to obtain isoform sequencing information, e.g., from patient samples is specifically also provided, as are methods for mitochondrial lineage tracing that employ the instant chimeric amplicon sequencing processes. Methods and systems for array nucleic acid sequence processing and interpretation are also provided.
A computer-implemented method for diagnosing a medical condition of a patient is provided. The method can include causing, using one or more processors, an excitation source to emit an excitation light towards a region of interest of an artery, receiving, using the one or more processors and a detector, imaging data of the region of interest of the artery, generating, using the one or more processors and the imaging data, an image of the region of interest, determining, using the one or more processors, a risk region of an atheromatous plaque, based on the imaging data, and determining, using the one or more processors, that the patient has a severe case of an atheromatous plaque, based on the determined risk region of the atheromatous plaque.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
The present disclosure provides a method of treating cancer in a subject in need thereof comprising administering a checkpoint inhibitor to the subject, and administering a MALT-1 inhibitor according to an intermittent dosage regimen.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
The development of new immunoregulatory small molecules represents a significant advance in immunotherapy. Provided herein are compounds, such as compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and compositions, methods, uses, and kits that may be used in immunotherapy. The compounds provided herein are responsible for immunomodulatory signaling through the TLR2 receptor and are therefore useful for the treatment and/or prevention of various diseases (e.g., metabolic diseases, inflammatory diseases, immune disorders, or proliferative diseases).
A61K 31/688 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/ or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
C12N 15/65 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
The present disclosure relates to a pharmaceutical composition, such as a dry powder inhalation formulation or an injectable formulation, comprising a mixture of an antiviral agent and a mast cell stabilizer. The present disclosure relates to a codrug comprising a residue of an antiviral agent covalently bonded via a labile bond to a residue of a compound of Formula (I) or Formula (II). The present disclosure further relates to a method of administering an antiviral agent and a Formula I/II compound, a pharmaceutical composition, or a codrug to treat coronavirus infection and/or associated inflammation.
Methods, systems, compositions and strategies for the use of ARMM-mediated delivery of molecules (e.g., biological molecules, small molecules, proteins, and nucleic acids (e.g., DNA, RNA), DNA plasmids shRNA, mRNA) to cells of the nervous system (e.g., central nervous system and peripheral nervous system).
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
76.
TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM
Disclosed are bispecific compounds (degraders) that target α-synuclein protein for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat neurodegenerative diseases.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
77.
ENHANCED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS
Enhanced virus-like particles (eVLPs), comprising a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins on the external side; and a cargo disposed in the core of the eVLP on the inside of the membrane, wherein the eVLP does not comprise an exogenous gag/pol protein, and methods of use thereof for delivery of the cargo to cells.
An infusion apparatus includes a housing and a chamber configured to be connected to the housing. The apparatus further includes a weight sensor coupled to a load connector connected to the housing and an optical sensor disposed in the housing. The weight sensor is configured to generate a first signal based on a measured weight of the fluid container attached to the housing in a weight-bearing configuration. The optical sensor is configured to generate a second signal based on detecting drops of the fluid traversing the chamber. The apparatus also includes a flow control mechanism to control a flow rate of the fluid into an outlet channel. The apparatus includes one or more processing devices configured to perform operations including transmitting a control signal to the flow control mechanism to adjust the flow rate.
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
G01G 17/06 - Apparatus for, or methods of, weighing material of special form or property for weighing fluids, e.g. gases, pastes having means for controlling the supply or discharge
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
G01F 1/72 - Devices for measuring pulsing fluid flows
G01F 1/661 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by measuring frequency, phase shift or propagation time of electromagnetic or other waves, e.g. using ultrasonic flowmeters using light
G01G 19/18 - Weighing apparatus or methods adapted for special purposes not provided for in groups for weighing suspended loads having electrical weight-sensitive devices
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
81.
SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES
The present disclosure provides novel methods for treating, preventing, ameliorating, inhibiting and/or delaying the onset of tauopathies. The methods comprise administering to the subject an effective amount of a small molecule peptidomimetic, such as (R)-2-amino-N- ((S)-l-(((S)-5-amino-l-(3-benzyl-l,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6- dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Described herein are methods of ablating a cell population using chimeric antigen receptors (CARs) targeting CD37, as well as related molecules and methods.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Systems and methods are provided that may facilitate the irrigation of an anatomic space. The irrigation system can include a tube manifold, a fluid reservoir, a waste fluid trap and an emulsification system. The emulsification system can be arranged at a distal end portion of the tube manifold and can be configured to be inserted into an anatomic space and emulsify organic material located within the anatomic space.
A system for integrated electric field simulation and neuronavigation includes a neuronavigation system configured to track an electromagnetic coil used for neuromodulation of a brain of a subject and an electric field simulation neural network coupled to the neuronavigation system. The electric field simulation neural network is configured to generate a simulated electric field for a region of interest based at least on a coil position and orientation, a magnetic field profile of the electromagnetic coil, and multimodal neuroimaging data associated with the subject. The system further includes a display coupled to the electric field simulation neural network and configured to display the simulated electric field. The region of interest can be the brain of the subject and the electromagnetic coil can be a transcranial magnetic stimulation (TMS) coil.
A system may transform sensor data from a sensor domain to an image domain using data-driven manifold learning techniques which may, for example, be implemented using neural networks. The sensor data may be generated by an image sensor, which may be part of an imaging system. Fully connected layers of a neural network in the system may be applied to the sensor data to apply an activation function to the sensor data. The activation function may be a hyperbolic tangent activation function. Convolutional layers may then be applied that convolve the output of the fully connected layers for high level feature extraction. An output layer may be applied to the output of the convolutional layers to deconvolve the output and produce image data in the image domain.
The General Hospital Corporation d/b/a Massachusetts General Hospital (USA)
Inventor
Tompkins, Ronald G.
Tzika, A. Aria
Yu, Yong-Ming
Rahme, Laurence
Martyn, Jeevendra A.
Abstract
The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury.
The disclosure provides methods of assessing a subject's risk of ascending thoracic aortic aneurysm or descending thoracic aortic aneurysm by detecting one or more single nucleotide polymorphisms (SNP) in one or more specific genes. The disclosure also provides methods of calculating a polygenic score to assess a subjects risk. Such methods may be used, for example, to identify asymptomatic subjects at risk for aneurysm.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
88.
SYSTEMS AND METHODS FOR NITRIC OXIDE GENERATION AND TREATMENT
Systems and methods for generating and delivering nitric oxide are provided. In one aspect, a nitric oxide generator includes an inlet arranged to receive a gas including nitrogen and oxygen, an outlet, a pair of electrodes arranged downstream of the inlet and configured to generate nitric oxide from the gas, a pressure regulator configured to selectively adjust a pressure of the gas surrounding the electrodes, an accumulator in communication with the pressure regulator, a nitric oxide sensor arranged to measure a concentration of nitric oxide at the outlet, and a controller in communication with the pair of electrodes, the pressure regulator, and the nitric oxide sensor. The controller is configured to selectively instruct the pressure regulator to adjust the pressure of the gas surrounding the electrodes in response to the concentration of nitric oxide measured at the outlet by the nitric oxide sensor.
The present disclosure features systems and methods for isolating target entities (TEs) found in target entity-secondary entity complexes within a biological fluid by exploiting interactions between TE, secondary entities (SEs), and/or engineered surfaces (ESs). TE isolation involves a two-step process in which TE-SE complexes are initially captured using, e.g., size-based approaches or binding interactions between SEs and ESs, and then TEs are specifically released from the captured TE-SE complexes using, e.g., biochemical means, such as disassociating enzymes and/or binding inhibitors, or using physical properties of fluid flow, e.g., flow velocity and/or shear rate.
The subject matter disclosed herein is generally directed to methods and compositions for a single- or multi-pot protocol for the efficient end to end capture of RNAs (inclusive of their poly- A tail or their 3' end). The invention includes the use of capture oligonucleotides containing a 3' non-extendable end and a selectively cleavable base upstream of an oligo-dT or oligo-dN and a 5' sequence containing unique molecular identifiers, and 2) a deoxyuracil glycosylase that acts only on a deoxyuracil present in a DNA:DNA duplex or DNA/RNA heteroduplex. The invention also includes the use of a dual template switching mechanism..
Systems and methods are provided for semi-automated, portable, ultrasound guided cannulation. The systems and methods provide for image analysis to provide for segmentation of vessels of interest from image data. The image analysis provides for guidance for insertion of a cannulation system into a subject which may be accomplished by a non-expert based upon the guidance provided. The guidance may include an indicator or a mechanical guide to guide a user for inserting the vascular cannulation system into a subject to penetrate the vessel of interest.
The invention provides molecular classifiers for use in the characterization and diagnosis of lung cancer and methods of selecting and treating subjects with appropriate personalized cancer treatments, including but not limited to CDK4/6 inhibitors, c-Met inhibitors, PD-1/PD-L1 inhibitors and combinations thereof.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
93.
PARALLEL ANTIBODY ENGINEERING COMPOSITIONS AND METHODS
The present invention discloses high-throughput methods for the creation of antibodies or antigen-binding fragments that can bind to single or multiple targets. Also disclosed are methods for using one or more antibodies or antigen-binding fragments to detect cognate binding partners in various types of samples.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
94.
METHODS AND SYSTEMS TO PRINT AND MATURE TISSUES OVER TIME IN A THREE-DIMENSIONAL SUPPORT MATRIX
A method of forming a tissue or an organ, including: disposing, in a support medium in a gel state, a composition comprising a live biologic; changing a state of the support medium from the gel state to a solid state; and supporting, in the support medium at the solid state, the live biologic in the composition.
The present disclosure relates to compositions and methods for single-cell nucleic acid sequencing, and specifically provides for pre-amplifying target nucleic acids in a manner that allows for more proportionate detection of all target nucleic acids, including low prevalence/abundance RNAs, from individual cells. The disclosure also provides for application of a series of barcoding steps to associate cell-specific identifiers (IDs) to the targeted nucleotide sequences, and ultimately provides for increased throughput capacity and greater accuracy of single-cell nucleic acid sequencing. Certain aspects of the present disclosure also provide for improved quantitative detection of nucleic acid sequence barcodes, which in embodiments allows for highly sensitive quantitative detection of barcoded antibody levels and/or highly sensitive quantitative detection of barcoded antibody-bound protein levels (e.g., where specific antibodies are labeled with a barcoded oligonucleotide that is specific to each barcoded antibody's target. In such approaches, the oligonucleotide barcode can serve as a target nucleic acid sequence for the capture probes of the instant disclosure. Compositions, methods and kits related to specific combinations of capture probes are also provided.
Methods of making consolidated blend(s) of polymeric material(s) with one or more therapeutic agents (such as an antibiotic) are provided, wherein the method comprises the steps of providing a polymeric material, blending the polymeric material with one or more therapeutic agent(s), pelletizing the blended polymeric material, environmentally treating by various approaches the pelletized polymeric material, and consolidating the environmentally treated pellet. Products made by the methods and uses of the products also are provided.
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
Methods and compositions for enhancing Wnt signaling pathway activities in a tissue of a subject have been developed for the treatment of cancer, in particular cancers with one or more mutations in the APC (adenomatous polyposis coli) gene. Preferably, the amount of the compositions for enhancing Wnt signaling does not reduce or inhibit proliferation or viability of normal healthy cells in the subject. In some embodiments, pharmaceutical compositions including an effective amount of one or more GSK-3 inhibitors are administered to reduce cancer cell proliferation or viability in a subject. A preferred GSK-3 inhibitor is LY2090314 encapsulated within, or associated with nanoparticles. Dosage forms of LY2090314 encapsulated within, or associated with nanoparticles for administration are also described.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
X-ray absorption of breast cancers and surrounding healthy tissue can be very similar, a situation that sometimes leads to missed cancers or false-positive diagnoses. To increase the accuracy of tomosynthesis and cancer diagnosis, dynamic X-ray elastography using a novel pulsed X-ray source synchronized to shear waves generated in a sample is described in the present disclosure. This imaging modality provides both absorption and mechanical properties of the imaged sample. A vibration source is used to vibrate the sample while a synchronously pulsed cold cathode X-ray source images the mechanical deformation. The generated stroboscopic images are further used to derive stiffness maps of the sample in addition to the conventional X-ray image.
The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C07K 14/35 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
